<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496209</url>
  </required_header>
  <id_info>
    <org_study_id>RECONSTRUCT</org_study_id>
    <nct_id>NCT01496209</nct_id>
  </id_info>
  <brief_title>REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts</brief_title>
  <acronym>RECONSTRUCT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double blinded and placebo-controlled, dose escalation, single-center safety and&#xD;
      preliminary efficacy study of cardiospheres delivered via NOGA MYOSTAR injection catheter in&#xD;
      subjects with chronic ischemic cardiomyopathy. The objective is to achieve and document&#xD;
      myocardial regeneration in patients with chronic scar.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Chronic Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group: Cardiosphere Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Allogeneic Human Cardiospheres (allogeneic CSps or alloCSps), a 3D micro-tissue heart-derived cell therapy product. Subjects will receive 150 million cell-equivalents of alloCSps via endomyocardial injection (10 million per site at 15 peri-infarct sites)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endomyocardial injections of allogeneic Human CSps</intervention_name>
    <description>NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.</description>
    <arm_group_label>Group: Cardiosphere Treatment</arm_group_label>
    <other_name>Biological: Allogeneic Human CSps (or alloCSps)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endomyocardial injections of vehicle only.</intervention_name>
    <description>NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with ischemic cardiomyopathy (EF &gt;10 and &lt;40% by functional imaging [ECHO, CT,&#xD;
             MRI, contrast ventriculography])&#xD;
&#xD;
          -  Symptomatic heart failure of NYHA Class 2 or 3&#xD;
&#xD;
          -  History of prior remote (&gt;3 mo) myocardial infarction and/or documented obstructive&#xD;
             coronary artery disease with corresponding dysfunctional segments by functional&#xD;
             imaging&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Ability to provide informed consent and follow-up with protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented myocardial infarction within 3 months (120 days)&#xD;
&#xD;
          -  Known or suspected left ventricular thrombus&#xD;
&#xD;
          -  Non-cardiovascular disease with life expectancy of &lt; 3 years&#xD;
&#xD;
          -  Absence of significant gadolinium-enhanced scar (&gt;10% of LV mass) at baseline MRIc&#xD;
&#xD;
          -  Positive panel-reactive antibodies (PRA)&#xD;
&#xD;
          -  Need for further revascularization clinically indicated at the time the patient is&#xD;
             assessed for participation in the clinical trial. This will be determined by a&#xD;
             cardiologist who is not an investigator in the clinical trial. No further&#xD;
             revascularization may be indicated by no arteries with significant stenosis, the&#xD;
             location, and extent of any stenosis may not be suitable for angioplasty, the distal&#xD;
             vessels may not be suitable for placement of bypass grafts, and/or the patient&#xD;
             declines angioplasty or bypass surgery.&#xD;
&#xD;
          -  NYHA IV heart failure&#xD;
&#xD;
          -  History of aortic stenosis/insufficiency&#xD;
&#xD;
          -  Requirement for chronic immunosuppressive therapy&#xD;
&#xD;
          -  Participation in an on-going protocol studying an experimental drug or device&#xD;
&#xD;
          -  Diagnosis of congenital or genetically-transmitted cardiomyopathy&#xD;
&#xD;
          -  Current alcohol or drug abuse because of anticipated difficulty in complying with&#xD;
             protocol-related procedures&#xD;
&#xD;
          -  Pregnancy or child-bearing potential without use of effective contraception. Men&#xD;
             intending to &quot;father&quot; children are also excluded.&#xD;
&#xD;
          -  Human Immunodeficiency virus infection&#xD;
&#xD;
          -  Viral hepatitis&#xD;
&#xD;
          -  Uncontrolled diabetes and/or hemoglobin A1C &gt; 8.5%&#xD;
&#xD;
          -  Abnormal liver function (SGPT &gt; 3 times the upper reference range) and/or hematology&#xD;
             (hematocrit &lt;25%, WBC &lt;3000, Platelets &lt;100,000) studies without a reversible,&#xD;
             identifiable cause&#xD;
&#xD;
          -  Ventricular tachycardia or fibrillation not associated with an acute ischemic episode&#xD;
&#xD;
          -  Canadian Cardiovascular Society Angina Class 3 or 4&#xD;
&#xD;
          -  History of cardiac tumor or cardiac tumor demonstrated or suspected on MRI other&#xD;
             imaging modality&#xD;
&#xD;
          -  Previous stem cell therapy/treatment&#xD;
&#xD;
          -  Individuals who are not fluent in English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Marban, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center, Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Eduardo Marban, MD, PhD</investigator_full_name>
    <investigator_title>Director, Heart Institute</investigator_title>
  </responsible_party>
  <keyword>Infarction</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Ventricular Dysfunction, Left</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Chronic Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

